SUPPLEMENTAL TABLES

Table A: Associations between Baseline Physical function and Changes in Actigraphy

Change in Actigraphy Measure	Spearman Correlation Coefficient	P-Value
Daytime Activity (n=23)	-0.64	0.001
Daytime Average Activity per Minute (n=23)	-0.70	0.0002
Daytime Maximum Activity (n=23)	-0.32	0.13
Variability in Activity (n=23)	-0.68	0.0003
Immobile Time (n=23)	0.29	0.18
Total Sleep Time (n=23)	0.37	0.08
Wake After Sleep Onset (n=22)	-0.13	0.57
Sleep Efficiency (n=22)	0.11	0.63
Total Activity at Night (n=22)	-0.21	0.35

Table B: Associations between Baseline Patient Characteristics and Changes in Actigraphy. BMI: body mass index

Baseline Covariate	Change in Actigraphy Measure	Spearman Correlation Coefficient	P-Value
Age (n=23)	Daytime Activity	0.36	0.09
Age (n=23)	Daytime Average Activity per Minute	0.41	0.052
Age (n=23)	Daytime Maximum Activity	0.05	0.82
Age (n=23)	Variability in Activity	0.24	0.27
Age (n=23)	Immobile Time	-0.34	0.11
Age (n=23)	Total Sleep Time	-0.43	0.039
Age (n=23)	Wake After Sleep Onset	-0.23	0.30
Age (n=23)	Sleep Efficiency	0.10	0.64
Age (n=23)	Total Activity at Night	-0.11	0.61
BMI (n=24)	Daytime Activity	0.48	0.017
BMI (n=24)	Daytime Average Activity per Minute	0.48	0.019
BMI (n=24)	Daytime Maximum Activity	-0.05	0.82
BMI (n=24)	Variability in Activity	0.49	0.016
BMI (n=24)	Immobile Time	-0.20	0.36
BMI (n=24)	Total Sleep Time	-0.22	0.31
BMI (n=23)	Wake After Sleep Onset	0.12	0.59
BMI (n=23)	Sleep Efficiency	-0.22	0.32
BMI (n=23)	Total Activity at Night	0.08	0.72

Table C: Association of Prior Chemotherapy and Changes in Actigraphy or Patient-reported Symptoms. PSQI: Pittsburgh Sleep Quality Index, FACT-ES: Functional Assessment of Cancer Therapy-Endocrine Subscale, BPI: Brief Pain Inventory

Variable	Odds Ratio (OR)	OR 95% CI	P-Value
Daytime Activity (n=24)	1.00	(1.00, 1.00)	0.69
Daytime Avg. Activity per Minute (n=24)	1.00	(0.98, 1.02)	0.79
Daytime Maximum Activity (n=24)	0.99	(0.99, 1.00)	0.06
Variability in Activity (n=24)	0.99	(0.95, 1.03)	0.59
Immobile Time (n=24)	0.99	(0.98, 1.01)	0.41
Total Sleep Time (n=24)	0.99	(0.98, 1.01)	0.41
Wake After Sleep Onset (n=25)	0.98	(0.95, 1.01)	0.23
Sleep Efficiency (n=25)	1.03	(0.89, 1.20)	0.68
Total Activity at Night (n=25)	1.00	(1.00, 1.00)	0.09
Sleep Time during Night Hours (n=25)	0.98	(0.95, 1.02)	0.37
Physical Function (n=29)	1.05	(0.91, 1.21)	0.52
Fatigue (n=30)	0.91	(0.80, 1.03)	0.13
FACT-ES (n=31)	1.05	(0.97, 1.14)	0.21
BPI Severity (n=29)	1.62	(0.74, 3.55)	0.22
BPI Interference (n=28)	1.03	(0.62, 1.72)	0.91
PSQI (n=29)	1.06	(0.79, 1.41)	0.70
Sleep Disturbance (n=30)	1.00	(0.89, 1.12)	0.96

Table D: Associations between Baseline Patient Characteristics and Changes in Patient-reported Symptoms. PSQI: Pittsburgh Sleep Quality Index, PROMIS: Patient-Reported Outcomes Measurement Information System, FACT-ES: Functional Assessment of Cancer Therapy-Endocrine Subscale, BPI: Brief Pain Inventory

Baseline Covariate	Change in Patient-reported Symptom	Spearman Correlation Coefficient	P-Value
Age (n=28)	PROMIS Physical Function	-0.04	0.86
Age (n=29)	PROMIS Fatigue	-0.17	0.38
Age (n=30)	FACT-ES	0.19	0.30
Age (n=28)	BPI Severity	-0.03	0.90
Age (n=27)	BPI Interference	-0.40	0.039
Age (n=28)	PSQI	-0.43	0.039
Age (n=29)	PROMIS Sleep Disturbance	0.04	0.82
BMI (n=29)	PROMIS Physical Function	0.18	0.34
BMI (n=30)	PROMIS Fatigue	-0.20	0.30
BMI (n=31)	FACT-ES	0.32	0.08
BMI (n=29)	BPI Severity	0.18	0.36
BMI (n=28)	BPI Interference	-0.01	0.95
BMI (n=29)	PSQI	0.09	0.65
BMI (n=30)	PROMIS Sleep Disturbance	-0.11	0.58